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Background: Chronic obstructive pulmonary disease (COPD) is recognized as a systemic illness with significant
extra-pulmonary features, such as exercise intolerance and muscle weakness. Pulmonary rehabilitation has been
shown to be very effective in counteracting these consequences in patients with more advanced COPD. However,
limited data is available on the efficacy of a physical exercise training programme in patients with mild to moderate
COPD in primary care. Furthermore, it is unknown if improved exercise capacity translates into enhanced daily
physical activities. The aim of this paper is to describe the design of a randomized controlled trial to assess the
efficacy of a physical exercise training programme in patients with mild to moderate COPD.
Methods/design: In this randomized controlled trial situated in the primary care setting, 102 patients with mild to
moderate airflow obstruction (FEV1≥ 50% of predicted), dyspnoea and a physically inactive lifestyle will be
randomized to an intervention or control group. The intervention group receives a 4-month physical exercise
training programme at a local physiotherapy practice, which includes exercise training, resistance training, breathing
exercises and advises on how to increase the level of physical activity. The control group receives usual care, i.e.
advises on how to increase the level of physical activity and a sham treatment at a local physiotherapy practice of
which no physiological training stimulus can be expected. Primary outcome is functional exercise capacity at
4-months measured on the six-minute walk distance. Secondary outcomes include peripheral muscle strength,
physical activity in daily life, health related quality of life, Medical Research Council (MRC) dyspnoea score and
patients’ perceived effectiveness. Follow-up measurement will take place at 6 months after baseline.
Discussion: This will be one of the first studies to evaluate the efficacy of a physical exercise training programme
in patients with mild to moderate COPD completely recruited and assessed in primary care. The results of this trial
may give a unique insight into the potential of the implementation of an easy, close-to-home rehabilitation
programme.
Trial registration: The Netherlands National Trial Register NTR1471.
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In patients with chronic obstructive pulmonary disease
(COPD), disease severity and prognosis are not only de-
termined by lung function impairment, but are also re-
lated to extra-pulmonary consequences of COPD such
as muscle weakness and exercise intolerance [1-3]. The
exercise training component of pulmonary rehabilitation
(PR) has been shown to be very effective in improving
exercise capacity, dyspnoea and quality of life [4]. As a
result, for patients with moderate to very severe COPD
and breathlessness (MRC dyspnoea score >2) exercise
training is recommended as part of PR in national and
international guidelines [1,5]. Another extra-pulmonary
feature of COPD is the decline in daily physical activity
(PA) [6]. Only a few trials have investigated the effect of
exercise training on changes in daily physical activity
[7-11]. These studies showed contradictory results, ran-
ging from significant improvements in PA [8,9] after
exercise training, to small or moderate effects [7,10] and
no effects at all [11]. Overall, current data indicate that
exercise training results in a significant but small effect on
PA and that larger randomized controlled trials (RCT’s)
are needed in this area [12].
A differentiation should be made in the improvement of
exercise capacity on the one hand and improvement of
daily physical activity on the other. Improvement in exer-
cise capacity fulfils the short-term goal of reducing breath-
lessness and fatigue [11], improving muscle strength and
thus lowers the barriers to be physically more active [10].
Regular physical activity in COPD patients has important
long-term health-related benefits, like a lower risk of
COPD related hospital admissions and decreased mor-
tality [13]. Furthermore, low physical activity has been
associated with systemic inflammation, cardiac dysfunc-
tion and lung function decline [13,14].
All abovementioned studies were performed in a clinical
or rehabilitation setting in COPD patients in more ad-
vanced GOLD stages [4]. However, patients with moderate
COPD also have impairments in exercise capacity, respira-
tory muscle function, limb muscle force and quality of life
[15-18]. In addition, the level of physical activity is already
decreased in patients with moderate COPD compared to
healthy control subjects [14,19,20]. Scant information is
available on the effects of community-based exercise train-
ing programmes in general and even less about their effect
on daily activity [9]. Exercise training programmes in pa-
tients with moderate to severe COPD, when incorporated
in (self)-management or integrated disease management
programmes in primary care, result in improvements in
health-related quality of life, breathlessness, exercise cap-
acity, muscle strength, daily physical activity, reduced hos-
pital admissions and hospital days per person [9,21-24].
Recruitment and assessment was done in the respiratory
department of general hospitals [9,21] or the interventionwas multifaceted (i.e. involved more than exercise therapy
alone) [22]. To our knowledge hardly any data are avail-
able on the efficacy of physical exercise training pro-
grammes in patients with mild to moderate COPD that
are recruited and treated solely in primary care.
Relevance
From a patients’ perspective, an increase in exercise
capacity and daily physical activity during the early
stage of the disease could be beneficial in order to stop
the downward spiral of symptom-induced inactivity,
deconditioning, muscle weakness, the fear of movement
and reduced quality of life. Since behavioural research
suggests that modifying behavioural patterns and cop-
ing styles takes time to be effective, regular exercise
should be started early in the course of the disease for
maximal effect [25]. It seems advantageous to initiate
exercise training when the symptoms of dyspnoea and
deconditioning are not very pronounced. Furthermore,
it is proposed that in patients with a relatively preserved
lung function, the physiological reserve for improve-
ment is much larger than in patients with (very) severe
disease [22].
Treatment of COPD at an early stage could also lessen
the burden of disease for society [26]. COPD is one of
the leading causes of morbidity and mortality worldwide
and imparts a substantial economic burden [27]. COPD-
related illness costs are disproportionately distributed,
with 10% of the patients (mostly patients in the more se-
vere stages of the disease) accounting for 73% of the total
costs, in which hospitalization is the largest contributor
[27]. An exercise training programme in primary care will
be a relatively cheap and an easily accessible intervention
for more patients than an expensive hospital-based re-
habilitation programme [28]. Although longitudinal stud-
ies are lacking, it is suggested that early recognition of
progression of exercise impairment especially in less ad-
vanced COPD patients is relevant to prevent further de-
terioration of functional capacity [22,29].
Current daily care for COPD
The Practice Guideline COPD of the Dutch College of
General Practitioners (NHG standard, 2007) recommends
general practitioners (GP’s) advise all patients with COPD
to be sufficient physically active [5]. Referral to a physical
exercise training programme in a physiotherapy setting is
advised only in patients with moderate to severe COPD,
who have impairments in physical functioning due to dys-
pnoea. As of 2010, there is a new development in the pri-
mary care organization of patients with chronic disease in
the Netherlands, including COPD. Disease management
programmes have regionally been developed by general
practitioners in collaboration with other caregivers in
primary care. General practitioners and/or the nurse
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lung function testing, prescription of pharmacotherapy
and counselling on smoking cessation, inhalation tech-
nique and physical activity. There is the possibility to refer
patients with mild to moderate COPD to registered physio-
therapists, experienced in COPD care. The implementation
of this disease management programme for COPD is en-
couraged by the reimbursement through so-called chained
diagnose-treatment combination (DTC) [29]. Although in
some regions in the Netherlands these disease manage-
ment programmes for COPD are already implemented and
serve as current daily care, no evidence on the effectiveness
of these programmes is available. In addition, no data are
available on the added value of a physical exercise training
programme compared to advice on increasing daily phys-
ical activity in usual care.Objectives
The primary objective of our study is to evaluate the effi-
cacy of a physical exercise training programme (PETP) in
patients with mild to moderate COPD in the primary care
setting on exercise capacity, physical activity, dyspnoea
and quality of life. The 6 month time point is aimed at
gaining more insight into the lasting of the effects.
The secondary objective is to assess how patient charac-
teristics and baseline burden of disease modify the effect
of a physical exercise training programme on functional
exercise capacity in patients with mild to moderate COPD
in primary care.REFERRAL OF
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Figure 1 Overview of the flow of the study.Methods/design
Study design
A randomized controlled trial performed in the primary
care setting in which the effects of a 4-month physical ex-
ercise training programme for patients with mild to mod-
erate COPD will be compared to a control programme.
The latter includes advices concerning physical activity ac-
cording to the Practice Guidelines of the Dutch College of
General Practitioners [5] and a sham-treatment (ST) in
physiotherapy practice.
General practice is the primary entrance for patients to
participate in the trial. If a patient is a potential trial partici-
pant, the GP or nurse practitioner explains to the patient
that it is important to enhance his physical activity level.
For professional support to achieve this goal, the patient is
referred to a COPD-certificated physiotherapist. If the pa-
tient is willing to undergo the physiotherapy treatment, he/
she makes an appointment at the physiotherapy practice.
The physiotherapist will give extensive information about
the study procedures and the patient will have one week to
consider participation in the trial. If the patient wants to
participate, randomization will take place after obtaining
informed consent. Patients of both treatment groups will
be assessed in physiotherapy practice at baseline, at the
end of the programme (after four months) and six months
after baseline assessment. The measurements done by the
physiotherapist are part of their routine assessments and
are imbedded in the intake procedures. The results of this
intake procedure will be the starting point of the treatment.
Figure 1 illustrates the flow of the study.INTER-
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proved the study protocol, procedures and informed con-
sent and the trial has been registered at The Netherlands
National Trial Register NTR1471.
Setting
This multicenter trial is coordinated by the CAPHRI
School for Public Health and Primary Care of Maastricht
University and conducted in several general practices
and physiotherapy practices in the southern part of the
Netherlands.
Study population
Participants for the trial will be recruited from general
practices in Limburg, in the southern part of the
Netherlands. There are 614 general practices in this region
covering a population of over 1.000.000 [30]. Statistics
suggest that 1,7% of the Dutch population is likely to have
COPD [31]. The population in Limburg is the least physic-
ally active population of the Netherlands [32].
Inclusion will be based on patients with a clinical diagno-
sis of mild to moderate COPD (post-bronchodilator FEV1/
FVC ratio < 0,7 and FEV1 ≥ 50% of predicted); who not
have a minimum of 30 minutes of physical activity at mod-
erate intensity, on at least 5 days per week, according to
the ACSM-recommendation [33]; having a stable situation
(no exacerbations in the last 8 weeks) and adequate and
optimal inhalation technique, are competent enough to
understand and speak the Dutch language and having pro-
vided written informed consent. According to the Practice
Guidelines of the Dutch College of General Practitioners, a
maximal cardiopulmonary exercise test prior to exercise
training will be conducted by a pulmonologist, cardiologist
or a sports medicine physician in COPD patients who suf-
fer from cardiopulmonary co morbidities [5,34].
Patients will be excluded from the trial, when they:
already receive or have received a physical exercise training
programme or rehabilitation therapy in the past year; have
had respiratory tract infections within the last 8 weeks; are
suffering from serious co morbid conditions, which would
interfere with regular exercise training (including severe
orthopaedic, muscular, neurological disorders or cardio-
vascular conditions) and patients who are expected to be
lost for follow-up (e.g. because of a planned change of resi-
dency or a long holiday break).
Randomization and blinding
After informed consent is obtained, patients will be ran-
domly assigned to the intervention group or the control
group in a 1:1 ratio, with the help of computer generated
random number tables. Randomization will be performed
by a centralized and independent person who has a con-
cealed list. The researcher is not involved in allocation to
treatment group or setting. Full blinding procedures arenot applicable in this study. The participating general
practitioners, nurse practitioners and physiotherapists and
also the patients cannot be blinded to allocation of indi-
viduals to the intervention group or control group. Al-
though patients will be aware of the existence of two
treatment arms, they are not informed about the exact
content of the other treatment arm. Also, patients of both
groups will not be in the same physiotherapy setting for
treatment at the same time. The researcher will be fully
blinded to the randomization list until the clinical data-
base is unlocked at the end of the trial.
Sample size calculation
We performed a pilot study in one physiotherapy setting
in order to get a rough idea of the improvement in six-
minute walk distance (6MWD) in this group of patients
after a 4-month physical exercise training programme.
Data of six patients with mild to moderate COPD were
collected. Their mean 6MWD was 475 metres with a
standard deviation of 62. These patients increased their
6MWD by a mean of 52 metres. Troosters et al. re-
ported a mean difference in change from baseline of 52
metres between the intervention group and control
group, in a study of the short- and longer-term benefits
of 6 months pulmonary rehabilitation [35]. A more re-
cent study showed an improvement of 54 metres with a
standard deviation of 78 metres after a 7 week pulmonary
rehabilitation programme [11]. Our assumptions for this
study are that the mean difference in change from baseline
between the intervention group and the control group (δ)
is 52 metres (52–0 m), with a standard deviation (σ) of 78
metres [11]. According to the effect size measures for two
independent groups this implies a large effect
size (Cohen’s d = δ/σ = 52/78 = 0.66) [36]. The sample size
needs to be 36 patients per treatment arm (72 in total),
whereby α = 0.05 (2 tailed), 80% power and a ratio of con-
trol to experimental patients of 1:1. This sample size calcu-
lation is done by using the PS power and sample size
program of Dupont and Plummer [37,38].
A total patient number of 102 participants (51 per
treatment arm) is needed, based on the abovementioned
calculation and allowing for dropouts (30%). Previous
studies showed a drop-out rate varying from 26 to 31%
[11,35,39,40].
Intervention
The treatment period is set at four months and consists of
either the physical exercise training programme or the
sham-treatment. The intervention will be carried out by
physiotherapists working in a primary care setting, with
broad expertise and education in COPD. The treatment
protocol is standardised, the Dutch Guideline Physiother-
apy in COPD serves as a framework, and based on indi-
vidual problems and possibilities of the patient [41].
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The physical exercise training programme has four main
goals; improvement in exercise capacity, muscle strength,
daily physical activity and breathing technique. The phys-
ical training component entails endurance training and/or
interval training [41]. Walking speed on the treadmill is
executed with an intensity of 75% or higher of the results
of the six-minute walk test (6MWT). Ratings of perceived
exertion and dyspnoea of five and higher on the modified
Borg-scale (0–10) are used to tailor exercise intensity [42].
Resistance training in addition to endurance or inter-
val training is recommended in all patients, especially
important in patients with peripheral muscle weakness.
In the absence of any comparative studies it is recom-
mended to use both upper limb and lower limb resist-
ance weight training at an intensity of at least 60-80% of
the one repetition maximum, 2 to 3 sets of 8–12 repeti-
tions are preferable [41].
Much emphasis is given to the assessment and treat-
ment of physical inactivity in daily life. Patients are ad-
vised to increase their total physical activity. Patient and
physiotherapist together define a strategy to meet the
ACSM-recommendation for physical activity, i.e. per-
forming moderately intense physical activity for 30 mi-
nutes on at least five days a week [33].
Breathing exercise is an embracing term for a range of
exercises such as active expiration, slow and deep
breathing, pursed lips breathing, relaxation therapy,
body positions such as forward leaning and diaphrag-
matic breathing [41].
The physical exercise training programme will consist of
two supervised sessions per week in the physiotherapy set-
ting in primary care. These sessions will be with 1–5 pa-
tients at the time and the duration of each session will be
60–90 minutes, depending on group size. From an organ-
isational and practical point of view it is not feasible to ask
patients to come to a physical therapy setting more often.
Furthermore, as mentioned before, an important part of
the programme is enhancement of daily physical activity.
So, patients are requested to perform an additional train-
ing session at home, including walking and/or cycling and
they have to report these activities weekly to the physio-
therapist. It is our aim to enhance the awareness and
responsibility of our patients to change their physical ac-
tivity behaviour for the long term and this encompasses
enhancement of self-management and self-efficacy.
Control group (sham-treatment)
According to the national guidelines of the Dutch College
of General Practitioners (NHG) and the Multidisciplinary
Guideline on non-pharmacological treatment of COPD,
the GP and the nurse practitioner should give advice to
improve the physical condition [5,43]. Verbal advice will
be supported by a written brochure. This brochure isdeveloped in collaboration with the NHG as part of a
preceding implementation project of physiotherapy for
COPD patients in primary care [44].
In addition, the patients in the control group will par-
ticipate in a sham-treatment at the physiotherapy prac-
tice. This treatment consists of 30 minutes once a week
“exercise” training, with ratings of perceived exertion
and dyspnoea of 2 or lower on a modified Borg-scale. It
is unlikely that a physiologic training stimulus will occur
at these levels of exertion. There will be no breathing ex-
ercises or resistance training. Furthermore, patients will
be advised to do at least 30 minutes of moderate intense
physical activities on at least five days a week according
to the ACSM-recommendation for physical activity [33].
Outcome measures
All outcomes will be assessed at baseline (T0), at the
end of intervention after four months (T1) and at the
end of follow-up (T2) at six months.
Primary outcome measure
The primary outcome measure will be the functional ex-
ercise capacity measured by the increase in the six-
minute walk distance (6MWD) at 4 months compared
to baseline. The six-minute walk test (6MWT) will be
performed in accordance with the ATS Statement:
guidelines for the 6MWT [45], except that a standard
30-meter corridor will not always be feasible in a pri-
mary care physiotherapy practice, but the minimal track
will be 10 meter. The results will be expressed in abso-
lute values and as percent of the predicted value [46].
During the walk test, perceived fatigue and dyspnoea will
be measured on a modified Borg scale ranging from zero
(nothing at all) to ten (very, very severe) [47]. Oxygen
saturation and pulse rate will be measured by a finger
pulse oximeter (Onyx 9500) [45].
Secondary outcome measures
Isometric handgrip force will be measured with a hy-
draulic handheld dynamometer (Yamar Preston, Jackson
MI). Peak handgrip force (in Newton) will be assessed at
the dominant side with the elbow at 90 degrees flexion,
with the underarm and wrist in neutral position [48].
Isometric knee extension and shoulder abduction force
will be measured in standardised positions by a hand-
held dynamometer by means of the break method
[42,49]. Peak torques will be measured at the dominant
side according to Andrews et al. [49]. At least three at-
tempts will be performed for all muscle tests.
Self-reported daily physical activity will be assessed by
the brief physical activity assessment tool [50]. Objective
daily physical activity will be measured during 3 con-
secutive days and nights with an accelerometer-based
activity monitor (Dynaport; McRoberts BV). Data of
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lected, like steps per day, total active time per day, time
spent in moderate intense physical activities and vigor-
ous activities and physical activity level (PAL). All pa-
tients will be carefully instructed on how the activity
monitor should be positioned and they will receive a
manual with clear instructions and figures. They will
also have to fill out a checklist to verify if their day was a
representative one and to indicate any possible hin-
drance of the activity monitor.
The level of dyspnoea will be assessed by the Medical
Research Council (MRC) dyspnoea score [51]. Specific
Health Related Quality of Life (HRQL) will be assessed
by means of the Clinical COPD Questionnaire (CCQ)
[52,53] and the Chronic Respiratory Questionnaire (CRQ-
SR) [54-56]. The global perceived effect (GPE) of the treat-
ment according to the patients will be measured on a GPE
scale [57,58].
Furthermore, the following baseline characteristics will
be measured, height, weight, Body Mass Index (BMI)
and level of motivation by means of the questionnaire
(Dutch translation) according to Miller and Rollnick
et al. [59-61].
Data analysis
The descriptive characteristics will be presented quantita-
tively as means (±standard deviation) for continuous vari-
ables and as medians for categorical variables and will be
presented for the total group, as well as for the separate
groups. Unpaired t-tests will be used to compare the ef-
fects of the treatment between the intervention group and
control group at the end of the physical exercise training
programme (4 months). P-values smaller than 0.05 will be
considered as statistically significant.
Group (intervention vs. control) by time (pretest vs.
posttests) repeated measurements analysis of variance
(RM ANOVA) will be performed to examine (1) interven-
tion main effect, (2) time main effect, and (3) intervention
by time interaction effect on each of the continuous pri-
mary and secondary outcomes. An analysis of covariance
will be done to evaluate the relationship between covari-
ates and the dependent variable. The random effect will
also be evaluated, since participants from both arms will
be nested within the same physiotherapy setting. To evalu-
ate which factors predict a positive outcome, i.e. the phys-
ical exercise training programme is effective, a multiple
linear regression analysis will be done, using interaction
terms between predictors and physical exercise. A pre-
dictor variable will make a significant contribution to pre-
dicting the outcome when P-value is smaller than 0.05.
The following possible predictors are taken into account,
baseline: MRC dyspnoea score, walking distance, periph-
eral muscle strength, level of daily physical activities and
compliance with the training programme [62-64].Discussion
This will be one of the first studies to evaluate the efficacy
of a physical exercise training programme in patients with
mild to moderate COPD completely recruited and assessed
in primary care. If the results of this study show that this
training programme is effective, this would mean a big step
ahead in the follow-up of patients with mild to moderate
COPD. Patients are actively involved in their disease man-
agement in an early phase and the intervention can ameli-
orate further deterioration and influence their prognosis in
the long term [22]. Exercise training has been shown to
positively affect some aspects of health status (exercise
capacity, muscle force, blood pressure, bone mass) [65].
Using an active lifestyle is necessary to break out of the
negative spiral of dyspnoea and deconditioning and is
probably essential for a long lasting change in improve-
ments in daily physical activity. The availability of a phys-
ical exercise training programme close to the patient’s
home most likely improves compliance to the enhanced
physical activity [22]. With this enhanced physical activity
and the benefits of an improved exercise capacity, a patient
can regain his social contacts [22]. This will give a great
impact of a patient’s quality of life.
Bias, confounders and limitations
From a methodological point of view, a cluster random-
ized design would be the most sound design for the
study. The rationale for performing an individually ran-
domized trial is that we observed in a pilot study [44],
that physiotherapists were not very keen to deliver a treat-
ment without a proper training programme, although
hard evidence of efficacy of a physical exercise training
programme COPD was still lacking. Therefore, it would
be impossible to recruit sufficient physiotherapy practices
with treating only control patients. We have found a solu-
tion to this problem by allowing the physiotherapist offer-
ing the possibility for patients in the control group to
participate in the physical exercise training programme
after the study-period, in case the intervention has proven
to be efficacious. To tackle contamination, we will train
and instruct the physiotherapists thoroughly in advance of
the study and monitor and instruct them throughout the
intervention period. Physiotherapists can only participate
if they are willing to deliver both the intervention treat-
ment and sham-treatment. Another strategy to minimize
contamination is that patients of the intervention and
control group will not be in the same physiotherapy set-
ting at the same time. So, the physiotherapists can focus
their mind on just one treatment at the time.
Both the physiotherapists and the patients are not
blinded during this study, since they are aware of the
treatment procedures. Physiotherapists will conduct the
measurements as well as the treatment in patients. Due
to practical considerations it is not feasible to perform
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a single researcher. To assure a high quality and uni-
vocal treatment, the participating physiotherapists will
be trained and instructed extensively before the start of
the training. Also, throughout the intervention period
the physiotherapists will be monitored continuously.
The researcher will visit the participating physiotherapy
practices frequently and will have regular contact by
telephone and email in order to check the compliance
with the treatment protocols.
As the population in Limburg is the least physically ac-
tive population of the Netherlands, this might influence
the external validity of the study. Another limitation is
that the six-minute walk tests are performed on different
tracks, which will influence the variability. An advantage
of the randomization on patient level instead of phy-
siotherapy practice level is that patients are assigned to
smaller and longer passages in a non-differential manner
and an equal distribution of patients from the intervention
group and control group can be expected per physiother-
apy practice. Since we are interested in the difference
scores (4 or 6 months minus baseline measurement) and
participants are assessed in the same passage on all occa-
sions, we think that the variability is acceptable.
Potential barriers
From the feasibility study of Faulkner et al. it is known
that recruitment of patients with moderate COPD for a
physical activity intervention in primary care is very dif-
ficult [40]. The reported main recruitment issue for
caregivers in that study was lack of available time to par-
ticipate in research activities [40]. Furthermore, in gen-
eral practice no objective tool to measure daily physical
activity is available, only subjective questionnaires. As
a consequence, general practitioners or practice nurses
might have a lack of information on this topic and will
not consider a follow-up strategy, including referral to a
physical exercise training programme.
One of the first major symptoms in COPD is exer-
tional breathlessness. To avoid confrontation with this
symptom, patients with COPD are more inclined to
adapt their lifestyle, for example taking the elevator in-
stead of climbing the stairs. In this way impairments in
daily life are not noticed by the patient. So, on patients’
level it might be a barrier that patients with only a mild
airway obstruction and moderate exercise limitation do
not feel the need to participate in a physical exercise
training programme [66]. In this mild to moderate cat-
egory, many patients will probably have work commit-
ments and lack of time might be a problem [40].
A key factor in the recruitment of patients is the team-
work between the different healthcare professionals in
primary care. From June 2006 till November 2007, our
research group has executed an implementation projectof physiotherapy for COPD patients in primary care in
the region to be studied [44]. One of the main objectives
was to start up and improve collaboration between gen-
eral practitioners, nurse practitioners and physiothera-
pists. As a result of the project referral policy of COPD
patients to physiotherapists in primary care in this re-
gion improved. In this way, we expect to minimize re-
cruitment problems.
Given the evidence of the efficacy of pulmonary rehabili-
tation on functional exercise capacity, dyspnoea and qual-
ity of life in patients with moderate to severe COPD, there
is now an urgent need to determine whether similar obser-
vations apply in the larger group of patients with earlier
disease characteristics [40].
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